Pulse: medical technology report 2012
New technologies are blurring the lines between medical devices, diagnostics and health IT, with the potential to revolutionize health care. Will your company be ready?
Cash on the prescription 2012
In 2011, Big Pharma reported weaker working capital performance compared with 2010. Pressured to improve shareholder value, what measures can companies undertake to restore performance?
Beyond borders: global biotech report 2012
As serious resource constraints continue to plague the industry, how can biotech innovation be sustained? Delve into our 26th edition for key findings and insights.
Progressions 2012: health care everywhere
Unsustainable costs and game-changing technologies are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report.
What Europe has to offer biotechnology companies
Europe has the potential to be a world leader in biotechnology, but more needs to be done by industry and regulatory authorities to get there.
Medical technology report 2011
Facing a confluence of risks — increasing regulatory, pricing and financing pressures, uncertain public policy climate and rapidly changing customer base — can medtech sustain innovation?
Beyond Borders 2011: global biotechnology report
Facing a confluence of risks — increasing regulatory, pricing and financing pressures, uncertain public policy climate and rapidly changing customer base — can medtech sustain innovation?
German Biotechnology Report 2011
Can the German biotech industry continue to grow at a pace that will help it maintain a sustainable future?
2011 Italian Biotechnology Report
How is the Italian biotechnology field balancing its growth in human health, agro-food, and industry work? Learn more about this growing market.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

Biotechnology

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

Take a closer look:

Pharmaceutical

Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

Take a closer look:

Medical technology

Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

Take a closer look:

Contact us

Contact a member of our global team.

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

Register now!

Disruptors: Revolutionizing Drug/Dx Reimbursement

11-12 March 2013
Philadelphia, PA

Join us at this premier event which brings together senior executives from leading product (pharma, medtech, biotech) companies along with payers, providers and policymakers to discuss the key issues that will set the product reimbursement agenda over the next few years.